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Abstract
With the recent emergence of Zika virus (ZIKV) diseases, increasing global concern has
driven the demand for a vaccine. One promising vaccine platform has presented itself in the
form of exosomes: a subgroup of extracellular vesicles released by many human cell types that
facilitate intercellular communication. The objective of this study is to engineer exosomes that
incorporate ZIKV structural proteins into its phospholipid bilayer. Previous studies indicate that
CD9 and CD63 proteins are highly enriched in exosomal membranes. From this, it was hypothe-
sized that attaching ZIKV genes to CD9 or CD63 to produce a gene fusion may enable exosomes
to act as antigen-presenting vesicles. These engineered exosomes may potentially stimulate T-cells
to mount a strong immune response. The cDNA of the CD9, CD63, and the highly immunogenic
ZIKV genes (envelope, precursor membrane, and NS1) were generated using RT-PCR. These
products were used as a template for regular PCR, and cloned into pcDNA3.1/V5 vector. The
chimeric gene fusion was assembled using the Gibson assembly kit, and transfected into human
embryonic kidney epithelial (HEK293T) cells for expression. The exosomes were purified from
the supernatant and subjected to immunoblotting and immunofluorescence assays to confirm the
presence of ZIKV proteins.
The results of this study are pending at the time of this abstract submission. A future study will be
conducted using an in vitro activation assay to determine if the engineered exosomes induce T-cell
activation. The potential candidates will be used in an animal study for immunity against ZIKV
infection.
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ABSTRACT 
With the recent emergence of Zika virus (ZIKV) diseases, increasing global concern has 
driven the demand for a vaccine. One promising vaccine platform has presented itself in the form 
of exosomes: a subgroup of extracellular vesicles released by many human cell types that facilitate 
intercellular communication. The objective of this study is to engineer exosomes that incorporate 
ZIKV structural proteins into its phospholipid bilayer. Previous studies indicate that CD9 and 
CD63 proteins are highly enriched in exosomal membranes. From this, it was hypothesized that 
attaching ZIKV genes to CD9 or CD63 to produce a gene fusion may enable exosomes to act as 
antigen-presenting vesicles. These engineered exosomes may potentially stimulate T-cells to 
mount a strong immune response. The cDNA of the CD9, CD63, and the highly immunogenic 
ZIKV genes (envelope, precursor membrane, and NS1) were generated using RT-PCR. These 
products were used as a template for regular PCR, and cloned into pcDNA3.1/V5 vector. The 
chimeric gene fusion was assembled using the Gibson assembly kit, and transfected into human 
embryonic kidney epithelial (HEK293T) cells for expression. The exosomes were purified from 
the supernatant and subjected to immunoblotting and immunofluorescence assays to confirm the 
presence of ZIKV proteins.  
The results of this study are pending at the time of this abstract submission. A future study 
will be conducted using an in vitro activation assay to determine if the engineered exosomes induce 
T-cell activation. The potential candidates will be used in an animal study for immunity against 
ZIKV infection.  
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